Amcor plc · AMCR · FY2024 Q3 · Calendar Q2 2024
Amcor raises guidance as destocking eases outside weak categories
Amcor's raised guidance, improving volumes and cost savings support a more constructive near-term operating picture, but the recovery remains uneven because healthcare and North American beverage are still weak.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about AMCR FY2024 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, management moved from maintained to raised guidance. Sequential volume trends improved as destocking eased, cost savings continued, and emerging-market demand strengthened; healthcare and North American beverage remained the main weak spots.
Guidance delta
Management raised full-year adjusted EPS guidance to $0.685-$0.71 and reaffirmed its $850-$950 million free-cash-flow target.
Key takeaways
- Volume trends improved sequentially as destocking abated, with stronger demand in emerging markets.
- Cost initiatives delivered about $130 million of savings, including $15 million from structural actions.
- Healthcare and North American beverage remained weak, although management expected improvement as destocking eased.
- The company continued returning capital through dividends and share repurchases while maintaining its free-cash-flow target.
Management priorities
- Continue structural cost reductions, including plant closures and workforce actions.
- Invest in emerging-market growth and differentiated packaging solutions.
- Advance sustainability efforts toward 100% recyclable or reusable packaging by 2025.
- Maintain dividend growth and share-repurchase programs.
Follow AMCR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 25, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| JP Morgan | Neutral | Overweight | Downgrade | Aug 17, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Aug 14, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 14, 2026 |
| Jefferies | Hold | Buy | Downgrade | Jul 22, 2026 |
| BMO Capital | Market Perform | Outperform | Downgrade | Jul 17, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 14, 2026 |
| Truist Securities | Buy | Buy | Maintain | May 7, 2026 |
| Deutsche Bank | Buy | Hold | Upgrade | Apr 1, 2026 |
| Baird | Outperform | Neutral | Upgrade | Jan 7, 2026 |
| UBS | Buy | Neutral | Upgrade | Jun 26, 2025 |
| Macquarie | Outperform | Neutral | Upgrade | Nov 27, 2024 |
| Goldman Sachs | Sell | Sell | Maintain | May 3, 2023 |
| CLSA | Buy | Buy | Maintain | Jul 19, 2022 |
| Seaport Global | Neutral | Neutral | Maintain | Oct 14, 2020 |
Named analyst price targets
Upside is calculated against the persisted current price $46.11. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | Michael Roxland | $51 | $46.2 | +10.6% | Aug 18, 2026 |
| UBS | Nathan Reilly | $56 | $47.11 | +21.4% | Aug 11, 2026 |
| Jefferies | Ramoun Lazar | $44.92 | $43.44 | -2.6% | Jul 21, 2026 |
| BMO Capital | Analyst unavailable | $47 | $44.84 | +1.9% | Jul 16, 2026 |
| Wells Fargo | Analyst unavailable | $43 | $42.78 | -6.7% | Jul 15, 2026 |
| Wells Fargo | Analyst unavailable | $41 | $36.69 | -11.1% | May 20, 2026 |
| Truist Financial | Michael Roxland | $50 | $40.74 | +8.4% | Apr 15, 2026 |
| Robert W. Baird | Analyst unavailable | $54 | $44.92 | +17.1% | Feb 4, 2026 |
| Morgan Stanley | Joseph Michael | $46 | $44.2 | -0.2% | Jan 28, 2026 |
| Robert W. Baird | Ghansham Panjabi | $50 | $42.85 | +8.4% | Jan 7, 2026 |
| Truist Financial | Michael Roxland | $60 | $42.3 | +30.1% | Jan 6, 2026 |
| Morgan Stanley | Joseph Michael | $57.5 | $42.3 | +24.7% | Nov 12, 2025 |
| Wells Fargo | Analyst unavailable | $45 | $40.5 | -2.4% | Oct 15, 2025 |
| Stifel Nicolaus | Analyst unavailable | $51 | $39.72 | +10.6% | Oct 10, 2025 |
| Goldman Sachs | Analyst unavailable | $82.5 | $41.15 | +78.9% | Sep 10, 2025 |
| Truist Financial | Michael Roxland | $55 | $48.3 | +19.3% | Jul 11, 2025 |
| Wells Fargo | Gabe Hajde | $54 | $56.7 | +17.1% | Oct 15, 2024 |
| Stifel Nicolaus | Lars Kjellberg | $54 | $48.15 | +17.1% | Jul 9, 2024 |
| Wells Fargo | Gabe Hajde | $49 | $49.05 | +6.3% | Jun 28, 2024 |
Track every rating change on AMCR the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAmcor plc stands as a prominent global provider of packaging solutions, focusing on the creation, production, and distribution of its diverse product portfolio across Europe, North America, Latin America, Africa, and the Asia Pacific regions. The company's operations are divided into two main segments: Flexibles and Rigid Packaging. The Flexibles division specializes in offering advanced flexible and film packaging solutions, catering to a wide array of industries including food and beverages, medical and pharmaceutical sectors, fresh produce, snack foods, and personal care items.…
Historical context
All AMCR earningsConsumer Cyclical peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| DECK Deckers Outdoor Corporation | FY2027 Q2 · Calendar Q4 2026 | +13.4% | -0.2% | Deckers raises FY2027 outlook as HOKA and UGG drive growth |
| TSCO Tractor Supply Company | FY2026 Q3 · Calendar Q4 2026 | +5.3% | +6.2% | Tractor Supply Q3: Pet and Digital Momentum Supports Margin Plan |
| PHM PulteGroup, Inc. | FY2026 Q3 · Calendar Q4 2026 | -4.5% | +5.8% | PulteGroup Holds Guidance as Buyer Traffic Slows |
| PKG Packaging Corporation of America | FY2026 Q3 · Calendar Q4 2026 | +3.8% | +4.2% | PCA beats Q3 expectations as Greif synergies offset cost pressure |
Latest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the AMCR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-11T06:39:45.180704+00:00
- Polygon adjusted daily market bars · 2026-10-25T00:10:44.196738+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-25T00:10:44.194039+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-25. For educational purposes only; not investment advice.